Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REFINE: Navitoclax Alone or with Ruxolitinib in Myelofibrosis
jRCT2041210029Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jul 2021
- Modality
- Small Molecules
01
Overview
Open-label trial of navitoclax and ruxolitinib in myelofibrosis (MF), primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and 1 more (2 arms), sponsored by AbbVie Inc. Primary endpoint: SVR35 at Week 24. Started Jul 2021; status: active, not recruiting.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on jRCT2041210029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041210029.